Skip to main navigation Skip to search Skip to main content

Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials

  • Ke Ren
  • , Hayam Hamdy
  • , Abdo Meyiah
  • , Eyad Elkord*
  • *Corresponding author for this work
    • Xi'an Jiaotong-Liverpool University
    • New Valley University

    Research output: Contribution to journal › Review article › peer-review

    12 Citations (Scopus)

    Abstract

    Lymphocyte-activation gene 3 (LAG-3) has emerged as a key immune checkpoint regulating immune responses in the context of cancer. The inhibitory effect of LAG-3-expressing T cells contributes to suppressing anti-tumor immunity and promoting tumor progression. This review discusses the function of LAG-3 in immune suppression, its interactions with ligands, and its potential as a prognostic biomarker for cancers. We also explore therapeutic strategies targeting LAG-3, including monoclonal antibodies, small molecule inhibitors, and CAR T cells. This review summarizes the current preclinical and clinical studies on LAG-3, highlighting the potential of therapeutic regimens targeting LAG-3 to enhance antitumor immunity and improve patients’ outcomes. Further studies are needed to fully elucidate the mechanism of action of LAG-3 and optimize its application in tumor therapy.

    Original languageEnglish
    Article number1501613
    JournalFrontiers in Immunology
    Volume15
    DOIs
    Publication statusPublished - 2024

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • LAG-3
    • T cells
    • biomarker
    • cancer
    • immune checkpoint

    Fingerprint

    Dive into the research topics of 'Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials'. Together they form a unique fingerprint.

    Cite this